Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Provided By GlobeNewswire
Last update: Nov 3, 2025
November 3, 2025
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP
First European patient expected to be enrolled in 4Q 2025
Read more at globenewswire.com6.5
+1.72 (+35.98%)
Find more stocks in the Stock Screener
BDRX Latest News and Analysis
